Wockhardt Ltd (NSE: WOCKPHARMA, BSE: 532300) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹33,061 Cr, it ranks #262 by market cap among the 6,197 Indian listed companies on FinBizNet, and #13 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,017.30 (as of 16 Nov 2026), the share price is 16.7% below its 52-week high of ₹2,422.30 and 85.6% above its 52-week low of ₹1,086.70. The share price is up 51.5% over one year and up 6.0% over three months.
| Current Price | ₹2,017.30 |
|---|---|
| Market Cap | ₹33,061 Cr |
| NSE Symbol | WOCKPHARMA |
| BSE Code | 532300 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 157.4 |
| Return on Equity | 4.00% |
| Return on Assets | 3.67% |
| 52-Week Range | ₹1,086.70 – ₹2,422.30 |
| 1-Year Price Change | +51.5% |
| 3-Month Price Change | +6.0% |
| Beta (1Y) | 0.98 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.wockhardt.com |
| Revenue | ₹969 Cr |
|---|---|
| Net Profit | ₹73 Cr |
| Net Margin | 7.5% |
| EPS (Basic) | ₹4.85 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Wockhardt Ltd reported revenue of ₹969 Cr in Q2 FY27, up 23.9% from ₹782 Cr in Q2 FY26 and up 4.3% from ₹929 Cr in Q1 FY27. It posted a net profit of ₹73 Cr for the quarter, against a net profit of ₹82 Cr in Q2 FY26 (down 11.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹738 Cr (Q1 FY26) to ₹969 Cr (Q2 FY27). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹969 Cr | ₹73 Cr | 7.5% |
| Q1 FY27 | ₹929 Cr | ₹107 Cr | 11.5% |
| Q4 FY26 | ₹965 Cr | ₹164 Cr | 17.0% |
| Q3 FY26 | ₹888 Cr | ₹61 Cr | 6.9% |
| Q2 FY26 | ₹782 Cr | ₹82 Cr | 10.5% |
| Q1 FY26 | ₹738 Cr | −₹108 Cr | −14.6% |
| Q4 FY25 | ₹743 Cr | −₹45 Cr | −6.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 49.32% of Wockhardt Ltd's shares as of Sept 2026, against 49.08% in Sept 2025 (+0.24 percentage points). Delivery averaged 37.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatiti
1. Others-This segment manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines. 2. Pharmaceutical Business-This segment comprises marketing of biopesticides and agro products.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Wockhardt Ltd | ₹33,061 Cr | 157.4 | 4.00% | ₹969 Cr | +51.5% |
Listed by market capitalisation. Ratios are shown for context only.
Wockhardt Ltd is trading at ₹2,017.30, with a market capitalisation of ₹33,061 Cr.
Wockhardt Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Wockhardt Ltd has a P/E of 157.4 and a return on equity of 4.00%.
Wockhardt Ltd is listed on the NSE under the symbol WOCKPHARMA and on the BSE under the scrip code 532300.
Wockhardt Ltd's share price is up 51.5% over one year and up 6.0% over three months. Its 52-week range is ₹1,086.70 to ₹2,422.30.
In Q2 FY27, Wockhardt Ltd reported revenue of ₹969 Cr and net profit of ₹73 Cr, with basic EPS of ₹4.85 (consolidated, parsed from the company's exchange filing).
Wockhardt Ltd reported revenue of ₹969 Cr in Q2 FY27, up 23.9% from ₹782 Cr in Q2 FY26 and up 4.3% from ₹929 Cr in Q1 FY27.
Promoters held 49.32% of Wockhardt Ltd's shares as of Sept 2026, against 49.08% in Sept 2025 (+0.24 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.